Company intelligence / Profile preview
Ocuvex Therapeutics
New Hyde Park, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Omlonti® (omidenepag isopropyl ophthalmic solution) 0.002%, a first-in-class EP2 receptor agonist, received FDA approval for ocular hypertension and open-angle glaucoma in September 2022. Additional assets (brimonidine, difluprednate) expected to launch through 2026, but clinical results not yet fully disclosed
- Therapeutic areas
- ImmunologyOphthalmology
- Modalities
- Small molecule (omidenepag isopropyl)Small molecule (brimonidine)Small molecule (difluprednate)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Merger with Visiox Pharmaceuticals completed August 2024pending merger with Onconetix announced July 2025
Beyond the preview
Go deeper on Ocuvex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocuvex Therapeutics.